

August 5, 2020

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ

Dear Sirs,

Sub: Compliance with Regulation 47(1)(b) of the SEBI Listing Regulations, 2015

Please find attached herewith copies of the newspaper publication of Un-audited Financial Results for the quarter ended June 30, 2020, published in Financial Express and Andhra Prabha on August 5, 2020 for your reference.

Thanking you,

Yours faithfully,

For Neuland Laboratories Limited



Sarada Bhamidipati
Company Secretary



Encl : As above



బుధవారం 5 ఆగస్టు 2020

NEULAND LABORATORIES LIMITED (CIN : L85195TG1984PLC004393)				
Regd. office: Sanali Info park, 'A' Block, Ground floor 8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034				
EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2020 (Amount in lakhs of ₹, unless otherwise stated)				
Sl. No.	Particulars	Quarter Ended 30.06.2020	Quarter Ended 30.06.2019	Year Ended 31.03.2020
1	Revenue from operations	20,542.38	18,100.75	76,271.08
2	Net profit for the period before tax	2,031.02	759.85	5,292.25
3	Net profit for the period after tax	1,516.30	570.71	1,621.05
4	Total comprehensive income for the period	1,521.16	581.31	1,577.65
5	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05
6	Other equity (excluding revaluation reserves) as shown in the audited balance sheet			69,621.83 As at 31.03.2020
7	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)			
	(a) Basic	11.82	4.45	12.63
	(b) Diluted	11.82	4.45	12.63

Note 1: The financial results for the quarter ended 30 June 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 04 August 2020.

Note 2: Key Standalone Financial Information:

Particulars	Quarter Ended 30.06.2020	Quarter Ended 30.06.2019	Year Ended 31.03.2020
Revenue from operations	20,542.38	18,100.75	76,271.08
Net profit for the period before tax	2,020.40	750.53	5,249.58
Net profit for the period after tax	1,505.68	561.39	1,588.01

Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.neulandlabs.com

By Order of the Board
For Neuland Laboratories Limited
Dr. D.R.Rao
Chairman & Managing Director
(DIN 00107737)

Place: Hyderabad
Date : 04 August 2020

FINANCIAL EXPRESS

WEDNESDAY, AUGUST 5, 2020

NEULAND LABORATORIES LIMITED (CIN : L85195TG1984PLC004393)				
Regd. office: Sanali Info park, 'A' Block, Ground floor 8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034				
EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2020 (Amount in lakhs of ₹, unless otherwise stated)				
Sl. No.	Particulars	Quarter Ended 30.06.2020	Quarter Ended 30.06.2019	Year Ended 31.03.2020
1	Revenue from operations	20,542.38	18,100.75	76,271.08
2	Net profit for the period before tax	2,031.02	759.85	5,292.25
3	Net profit for the period after tax	1,516.30	570.71	1,621.05
4	Total comprehensive income for the period	1,521.16	581.31	1,577.65
5	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05
6	Other equity (excluding revaluation reserves) as shown in the audited balance sheet			69,621.83 As at 31.03.2020
7	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)			
	(a) Basic	11.82	4.45	12.63
	(b) Diluted	11.82	4.45	12.63

Note 1: The financial results for the quarter ended 30 June 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 04 August 2020.

Note 2: Key Standalone Financial Information:

Particulars	Quarter Ended 30.06.2020	Quarter Ended 30.06.2019	Year Ended 31.03.2020
Revenue from operations	20,542.38	18,100.75	76,271.08
Net profit for the period before tax	2,020.40	750.53	5,249.58
Net profit for the period after tax	1,505.68	561.39	1,588.01

Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.neulandlabs.com

By Order of the Board
For Neuland Laboratories Limited
Dr. D.R.Rao
Chairman & Managing Director
(DIN 00107737)

Place: Hyderabad
Date : 04 August 2020